ST-3595 (Table 3), an inhibitor of hydroxamate-based histone deacetylase (HDAC), exhibited anti-proliferative and cytotoxic effects on PANC-1, AsPC-1, and Mia-PaCa-2 pancreatic cancer lines and human-derived pancreatic cancer cells [103]. Here, HDAC9 is linked to familial pancreatic carcinoma.